Novo Nordisk Raises Outlook as Wegovy Growth Disappoints

 The.Ticker.Guru
 
  The.Ticker.Guru
 
Follow  Message
 
 
Rising.Stars identifying stocks that finish the trading day with impressive gains. With a focus on market dynamics and late-day trading patterns.
 

•  04 Aug 2026
 

$NVO Novo Nordisk delivered better than expected second quarter 2026 results and raised its annual outlook, yet shares of the Danish pharmaceutical company fell about 6% after the report. The decline did not reflect weakness in the quarterly results, but investor concern that the company future growth engine, the Wegovy weight loss pill, is not expanding fast enough to justify elevated expectations. The earnings catalyst therefore shifted attention from the reported beat to the pace of future product adoption.

Second quarter sales reached 78.5 billion Danish kroner, approximately $12.1 billion, representing 3% growth at constant exchange rates. Adjusted operating profit totaled 33.4 billion Danish kroner, up 11% and above analyst expectations of about 28.7 billion Danish kroner. Adjusted earnings per share reached $0.96 compared with the $0.82 forecast, while revenue also exceeded early analyst expectations.

Net income declined despite the stronger operating performance. Novo Nordisk reported net profit of 20.99 billion Danish kroner, down 21% from the same period last year. The decline partly reflected one time accounting impairments totaling 6.3 billion Danish kroner related to intangible assets in the drug pipeline. These included an impairment of approximately 4 billion Danish kroner for the experimental obesity drug monlunabant.

Novo Nordisk raised its 2026 outlook following the results. The company now expects sales and adjusted operating profit to range between unchanged and a decline of as much as 6% compared with 2025. Its previous outlook called for a decline of 4% to 12% in both measures. The revision strengthened earnings momentum even as the stock reaction showed that investors were focused elsewhere.

Chief Executive Officer Mike Doustdar said stronger GLP-1 momentum in the United States, together with continued growth and new launches across international operations, led the company to raise its 2026 sales and adjusted operating profit outlook again. The statement highlighted continued demand across the existing portfolio. Institutional flows nevertheless remained sensitive to the performance of the next generation product.

The central factor behind the investor reaction was the performance of the Wegovy pill. The product is intended to become the company next growth engine and expand the market beyond weekly injections. Novo Nordisk said the pill passed 5 million prescriptions in the United States since its January launch. Weekly prescriptions exceeded 265,000 during the week ended July 17.

The Wegovy pill was launched in the United Arab Emirates in June and in the United Kingdom in July. Additional launches are expected across international markets. The geographic rollout shows continued expansion, but the market focused on the pace of revenue conversion rather than prescription growth alone.

Second quarter sales of the Wegovy pill reached approximately 3.2 billion Danish kroner, slightly below market expectations. Although the gap was relatively small, investors interpreted it as a sign that adoption could be slower than the aggressive forecasts built around the product. The negative reaction reflects a change in Wall Street expectations, with Novo Nordisk now judged not only on current Wegovy and Ozempic growth but also on its ability to preserve a competitive advantage in what is expected to become one of the largest pharmaceutical markets in the world.

Novo Nordisk main competitor is Eli Lilly, which currently leads significant portions of the United States obesity drug market through Mounjaro and Zepbound. The two companies hold most of the GLP-1 market, but investors are concerned that the advantage Novo Nordisk held in recent years is eroding. Eli Lilly continues to launch new products and invest in its pipeline, while Novo Nordisk is attempting to defend its position by expanding the Wegovy family through oral versions and higher doses.

The European regulator approved the Wegovy pill in July, along with a higher 7.2 milligram injectable dose of Wegovy. Novo Nordisk has already begun marketing the higher dose in the United States and the United Kingdom. Broader availability in Europe is expected during the second half of 2026. Successful expansion could support future multiple expansion if adoption accelerates.

Novo Nordisk also faces questions regarding future developments outside the GLP-1 market. The failure of an advanced trial for the cardiovascular drug ziltivekimab weakened one of the company hopes for diversifying its growth engines. The setback increased the importance of maintaining leadership in obesity treatments.

Novo Nordisk results were strong and exceeded expectations, but the share reaction highlighted the high threshold investors have set for the company. After the sharp decline in the stock over the past year, the market is seeking more than stability. It is demanding proof that Novo Nordisk can regain leadership in the obesity drug race against Eli Lilly.

View all market intelligence